Shares of Intrexon Corp (NYSE:XON) have received a consensus recommendation of “Hold” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $33.14.

XON has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Intrexon from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Thursday. Stifel Nicolaus initiated coverage on shares of Intrexon in a research report on Tuesday, July 17th. They issued a “buy” rating and a $72.00 target price for the company. Finally, Bank of America downgraded shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 target price for the company. in a research report on Monday, July 16th.

In other Intrexon news, insider Helen Sabzevari sold 8,402 shares of Intrexon stock in a transaction that occurred on Wednesday, July 18th. The shares were sold at an average price of $14.54, for a total value of $122,165.08. Following the completion of the sale, the insider now owns 25,000 shares of the company’s stock, valued at approximately $363,500. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Randal J. Kirk bought 7,479,431 shares of the business’s stock in a transaction on Tuesday, July 3rd. The stock was bought at an average cost of $13.37 per share, with a total value of $99,999,992.47. The disclosure for this purchase can be found here. Insiders own 48.20% of the company’s stock.

Large investors have recently bought and sold shares of the business. Two Sigma Advisers LP bought a new stake in Intrexon in the 4th quarter worth approximately $124,000. Xact Kapitalforvaltning AB bought a new stake in shares of Intrexon during the 4th quarter valued at $138,000. BB&T Securities LLC bought a new stake in shares of Intrexon during the 2nd quarter valued at $175,000. Mission Wealth Management LP bought a new stake in shares of Intrexon during the 2nd quarter valued at $182,000. Finally, Chessman Wealth Strategies RIA bought a new stake in shares of Intrexon during the 2nd quarter valued at $205,000. 82.16% of the stock is owned by institutional investors and hedge funds.

NYSE XON traded up $0.16 during mid-day trading on Friday, reaching $14.36. The stock had a trading volume of 624,300 shares, compared to its average volume of 1,554,870. Intrexon has a 1 year low of $10.26 and a 1 year high of $20.67. The firm has a market cap of $1.95 billion, a P/E ratio of -15.62 and a beta of 1.08. The company has a quick ratio of 1.93, a current ratio of 2.16 and a debt-to-equity ratio of 0.01.

Intrexon (NYSE:XON) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.28). Intrexon had a negative return on equity of 17.22% and a negative net margin of 82.17%. The firm had revenue of $45.30 million during the quarter, compared to analysts’ expectations of $51.70 million. During the same quarter in the previous year, the firm earned ($0.16) earnings per share. equities analysts expect that Intrexon will post -0.86 earnings per share for the current fiscal year.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Further Reading: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with's FREE daily email newsletter.